Tango Therapeutics Appoints Sung Lee to Board of Directors
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: GlobeNewswire
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung’s proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into registrational studies and continue to build and evolve our organization to support late-stage clinical development activities." Sung Lee currently serves as Executive Vice President and Chief Financial Officer at Cytokinetics, a role he assumed in May 2024. Prior to joining Cytokinetics, he held th
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Does Tango Therapeutics' (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed SuccessorGlobeNewswire
- Tango Therapeutics Appoints Sung Lee to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
TNGX
Earnings
- 11/4/25 - Beat
TNGX
Sec Filings
- 1/12/26 - Form 4
- 1/8/26 - Form 8-K
- 1/6/26 - Form 4
- TNGX's page on the SEC website